Cesar Rigoberto Molina, MD
Cardiovascular Disease (Cardiology) · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 6 carriers
- Offices
- 3
Offices
3 locations · El Camino Health Medical Network LLC · Physician Services at El Camino Hospital
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
21 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Molina’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G45862 · Current
Licensed to practise in California · since 1981 · expires 2027-03-31 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$380,375
Medicare paid this office $380,375 for 908 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 493 | $136,328 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 268 | $53,235 | $190 |
| Long return visit (40+ min) | 173 | $41,554 | $168 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 129 | $29,755 | $225 |
| Telephone medical discussion with physician, 21-30 minutes | 123 | $26,931 | $116 |
See all 28 services
| Return visit (30+ min) | 493 | $136,328 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 268 | $53,235 | $190 |
| Long return visit (40+ min) | 173 | $41,554 | $168 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 129 | $29,755 | $225 |
| Telephone medical discussion with physician, 21-30 minutes | 123 | $26,931 | $116 |
| Transitional care management services for problem of high complexity | 43 | $13,571 | $271 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 470 | $8,189 | $13 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 354 | $7,889 | $12 |
| New patient visit (45+ min) | 50 | $6,922 | $138 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $6,387 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $5,984 | $107 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 35 | $5,560 | $159 |
| Short return visit (20+ min) | 58 | $5,534 | $84 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 25 | $5,352 | $62 |
| Transitional care management services for problem of at least moderate complexity | 18 | $3,786 | $199 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 334 | $3,225 | $7 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 18 | $3,050 | $82 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $2,324 | $83 |
| New patient visit (60+ min) | 12 | $2,133 | $178 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 24 | $1,612 | $62 |
| New patient visit (30+ min) | 14 | $1,306 | $93 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 56 | $1,146 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 15 | $1,029 | $54 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 14 | $968 | $69 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 56 | $711 | $12 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 22 | $482 | $22 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 26 | $388 | $6 |
| Heart rhythm recording of continous external ekg over 8-15 days | 21 | $277 | $13 |
Who their Medicare patients are
908 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 28% · Women 48% · Also on Medicaid 9% · Health risk score 1.50. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 48% · Atrial fibrillation 35% · Diabetes 30% · Chronic kidney disease 30% · Heart failure 23% · Cancer 21% · Depression 19% · COPD 16% · Stroke 14% · Dementia 12%.
The office billed $1,519,602, Medicare allowed $506,608 and paid $380,375; for 4,616 services of 44 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 908 | 4,616 | 79 | 1.50 | $1,519,602 | $380,375 |
| 2023 | 844 | 3,919 | 79 | 1.49 | $1,307,288 | $323,414 |
| 2022 | 903 | 3,858 | 79 | 1.49 | $1,286,649 | $306,527 |
| 2021 | 872 | 4,278 | 79 | 1.46 | $1,460,228 | $381,155 |
| 2020 | 688 | 2,999 | 79 | 1.56 | $876,708 | $220,754 |
| 2019 | 887 | 4,748 | 78 | 1.57 | $1,092,784 | $314,594 |
| 2018 | 832 | 3,926 | 78 | 1.54 | $430,388 | $293,701 |
| 2017 | 834 | 4,320 | 78 | 1.66 | $446,407 | $336,260 |
| 2016 | 870 | 5,087 | 78 | 1.47 | $475,575 | $309,027 |
| 2015 | 904 | 5,311 | 78 | 1.59 | $497,923 | $335,211 |
| 2014 | 713 | 6,723 | 78 | 1.25 | $580,578 | $415,042 |
| 2013 | 1,483 | 8,557 | 79 | 1.55 | $897,963 | $613,174 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 27 services
| Return visit (30+ min) | 455 | $126,382 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 232 | $50,044 | $197 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 122 | $27,435 | $223 |
| Telephone medical discussion with physician, 21-30 minutes | 147 | $26,918 | $114 |
| Long return visit (40+ min) | 116 | $22,915 | $159 |
| Transitional care management services for problem of high complexity | 31 | $9,549 | $273 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 292 | $6,551 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 380 | $6,080 | $14 |
| New patient visit (45+ min) | 37 | $5,715 | $150 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 20 | $5,210 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $5,046 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,158 | $160 |
| New patient visit (60+ min) | 21 | $4,021 | $191 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 21 | $3,350 | $160 |
| Transitional care management services for problem of at least moderate complexity | 14 | $3,057 | $204 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 320 | $2,559 | $6 |
| Short return visit (20+ min) | 25 | $1,970 | $76 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,546 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 18 | $1,462 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 18 | $1,258 | $70 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 58 | $1,237 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 18 | $1,201 | $60 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 55 | $727 | $13 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 12 | $544 | $23 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 15 | $383 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 14 | $196 | $12 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 15 | $129 | $6 |
2022: 27 services
| Return visit (30+ min) | 466 | $122,516 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 207 | $42,279 | $195 |
| Long return visit (40+ min) | 132 | $30,233 | $163 |
| Telephone medical discussion with physician, 21-30 minutes | 108 | $20,681 | $104 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 78 | $17,865 | $221 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $8,852 | $181 |
| Transitional care management services for problem of high complexity | 26 | $7,412 | $275 |
| New patient visit (45+ min) | 46 | $6,112 | $133 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 286 | $5,784 | $11 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 349 | $5,171 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $5,138 | $93 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 30 | $4,782 | $159 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 69 | $4,580 | $65 |
| New patient visit (60+ min) | 20 | $3,537 | $177 |
| Transitional care management services for problem of at least moderate complexity | 15 | $3,246 | $203 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 337 | $3,226 | $7 |
| Short return visit (20+ min) | 33 | $2,941 | $84 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,351 | $75 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 12 | $804 | $67 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 34 | $697 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 15 | $678 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 16 | $612 | $24 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 13 | $576 | $22 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 34 | $503 | $14 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 17 | $362 | $20 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 23 | $353 | $6 |
| Heart rhythm recording of continous external ekg over 8-15 days | 16 | $232 | $14 |
2021: 25 services
| Return visit (30+ min) | 482 | $134,490 | $116 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 275 | $61,988 | $212 |
| Long return visit (40+ min) | 139 | $33,659 | $172 |
| Telephone medical discussion with physician, 21-30 minutes | 152 | $31,503 | $113 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 113 | $29,018 | $252 |
| Transitional care management services for problem of high complexity | 45 | $14,936 | $277 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $8,457 | $184 |
| New patient visit (60+ min) | 45 | $7,958 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $7,239 | $95 |
| New patient visit (45+ min) | 43 | $6,270 | $146 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 286 | $5,892 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 332 | $5,388 | $14 |
| Transitional care management services for problem of at least moderate complexity | 22 | $4,640 | $202 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 56 | $3,820 | $64 |
| Short return visit (20+ min) | 33 | $3,632 | $81 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 301 | $2,938 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 29 | $1,843 | $26 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 29 | $1,787 | $24 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $1,293 | $72 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 47 | $1,117 | $23 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 46 | $1,101 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 15 | $1,049 | $55 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 48 | $814 | $16 |
| Heart rhythm recording of continous external ekg over 8-15 days | 47 | $738 | $15 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 32 | $454 | $6 |
2020: 24 services
| Return visit (30+ min) | 417 | $81,991 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 156 | $33,979 | $208 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 65 | $15,985 | $239 |
| Long return visit (40+ min) | 79 | $14,609 | $125 |
| Ultrasound of both sides of head and neck blood flow | 52 | $10,564 | $192 |
| Transitional care management services for problem of high complexity | 26 | $7,240 | $226 |
| New patient visit (60+ min) | 42 | $7,126 | $170 |
| Short return visit (20+ min) | 64 | $5,526 | $67 |
| Telephone medical discussion with physician, 21-30 minutes | 37 | $4,443 | $99 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 253 | $4,272 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,939 | $179 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 226 | $3,493 | $11 |
| Telephone medical discussion with physician, 11-20 minutes | 33 | $3,215 | $68 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 36 | $2,594 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 210 | $2,198 | $8 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 16 | $1,659 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 35 | $1,265 | $23 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 15 | $1,138 | $20 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 29 | $946 | $22 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 32 | $733 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 26 | $627 | $22 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $237 | $22 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 24 | $230 | $6 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 14 | $104 | $5 |
2019: 30 services
| Return visit (30+ min) | 476 | $101,121 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 207 | $47,231 | $207 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 116 | $27,042 | $227 |
| Ultrasound of both sides of head and neck blood flow | 79 | $18,413 | $205 |
| Long return visit (40+ min) | 112 | $17,542 | $123 |
| New patient visit (60+ min) | 63 | $11,281 | $179 |
| Transitional care management services for problem of high complexity | 41 | $10,552 | $220 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $9,949 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $9,175 | $173 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 369 | $8,939 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 336 | $5,973 | $15 |
| Short return visit (20+ min) | 40 | $4,294 | $70 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 47 | $3,604 | $63 |
| Transitional care management services for problem of at least moderate complexity | 19 | $3,133 | $157 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 345 | $3,131 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 35 | $2,550 | $26 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 14 | $2,317 | $24 |
| Annual depression screening, 5 to 15 minutes | 103 | $2,288 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 33 | $2,153 | $25 |
| Programming of dual lead pacemaker system | 24 | $1,748 | $58 |
| External ekg recording for more than 48 hours up to 21 days | 60 | $1,677 | $25 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 62 | $1,637 | $23 |
| Complete ultrasound study of arm and leg arteries | 13 | $1,588 | $122 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 23 | $1,332 | $42 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 43 | $935 | $6 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 14 | $686 | $13 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 18 | $581 | $8 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $359 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 18 | $243 | $14 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 15 | $114 | $8 |
2018: 27 services
| Return visit (30+ min) | 444 | $92,340 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 186 | $43,800 | $223 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 124 | $32,524 | $252 |
| Long return visit (40+ min) | 97 | $16,167 | $142 |
| Ultrasound of both sides of head and neck blood flow | 62 | $14,859 | $209 |
| New patient visit (60+ min) | 47 | $9,343 | $199 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $9,265 | $99 |
| Transitional care management services for problem of high complexity | 31 | $8,622 | $233 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $8,443 | $192 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 300 | $6,588 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 286 | $4,879 | $15 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 26 | $3,737 | $144 |
| Annual depression screening, 5 to 15 minutes | 142 | $3,377 | $24 |
| Short return visit (20+ min) | 19 | $3,133 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 335 | $3,119 | $8 |
| Transitional care management services for problem of at least moderate complexity | 14 | $2,672 | $167 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 34 | $2,172 | $62 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 55 | $1,489 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 24 | $1,411 | $28 |
| External ekg recording for more than 48 hours up to 21 days | 38 | $1,300 | $30 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 22 | $1,205 | $27 |
| Programming of dual lead pacemaker system | 14 | $1,095 | $58 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 37 | $1,003 | $23 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 39 | $641 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $448 | $37 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 11 | $378 | $9 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 14 | $189 | $13 |
2017: 28 services
| Return visit (30+ min) | 415 | $103,512 | $107 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 175 | $47,843 | $263 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 110 | $37,219 | $315 |
| Long return visit (40+ min) | 110 | $24,073 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $19,959 | $107 |
| Transitional care management services for problem of high complexity | 34 | $12,103 | $252 |
| Ultrasound of both sides of head and neck blood flow | 38 | $9,021 | $226 |
| New patient visit (60+ min) | 43 | $8,797 | $205 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $8,156 | $204 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 275 | $7,096 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 260 | $5,177 | $17 |
| Annual depression screening, 5 to 15 minutes | 164 | $4,168 | $25 |
| Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | 12 | $4,089 | $114 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 42 | $3,441 | $66 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 340 | $3,324 | $8 |
| Transitional care management services for problem of at least moderate complexity | 14 | $2,523 | $180 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $2,495 | $156 |
| Short return visit (20+ min) | 18 | $2,228 | $70 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 27 | $2,222 | $29 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 22 | $1,967 | $32 |
| External ekg recording for more than 48 hours up to 21 days | 59 | $1,779 | $27 |
| Programming of dual lead pacemaker system | 20 | $1,658 | $57 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 54 | $1,326 | $22 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 40 | $1,203 | $7 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 44 | $1,197 | $20 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 29 | $1,020 | $10 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 11 | $722 | $13 |
| Administration and interpretation of patient-focused health risk assessment | 20 | $108 | $5 |
2016: 33 services
| Return visit (30+ min) | 448 | $92,004 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 220 | $53,558 | $227 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 100 | $27,741 | $272 |
| Long return visit (40+ min) | 125 | $20,657 | $124 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 17 | $8,463 | $498 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $7,671 | $92 |
| Transitional care management services for problem of high complexity | 28 | $7,204 | $218 |
| Ultrasound of both sides of head and neck blood flow | 32 | $6,941 | $193 |
| New patient visit (60+ min) | 39 | $6,866 | $176 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 301 | $6,482 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $6,476 | $180 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 306 | $5,191 | $15 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 33 | $4,451 | $135 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 17 | $4,294 | $95 |
| Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | 20 | $3,928 | $96 |
| Annual depression screening, 5 to 15 minutes | 166 | $3,591 | $22 |
| Short return visit (20+ min) | 20 | $3,099 | $61 |
| Transitional care management services for problem of at least moderate complexity | 18 | $2,963 | $156 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 322 | $2,763 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 31 | $2,339 | $27 |
| External ekg recording for more than 48 hours up to 21 days | 70 | $2,164 | $27 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 31 | $1,891 | $56 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 11 | $1,856 | $60 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 71 | $1,743 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 22 | $1,716 | $30 |
| Programming of dual lead pacemaker system | 24 | $1,702 | $52 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 37 | $1,361 | $8 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,360 | $113 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 48 | $1,077 | $19 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 13 | $932 | $12 |
| Programming of single lead pacemaker system | 11 | $723 | $45 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 41 | $577 | $6 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 15 | $331 | None |
2015: 32 services
| Return visit (30+ min) | 464 | $94,941 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 232 | $53,236 | $222 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 125 | $34,615 | $268 |
| Long return visit (40+ min) | 108 | $17,604 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $15,213 | $92 |
| Ultrasound of both sides of head and neck blood flow | 74 | $14,690 | $193 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 98 | $13,209 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $10,133 | $178 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 15 | $7,439 | $496 |
| New patient visit (60+ min) | 36 | $6,325 | $176 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 15 | $5,932 | $132 |
| Transitional care management services for problem of high complexity | 24 | $5,396 | $216 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 298 | $5,157 | $15 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 272 | $4,840 | $11 |
| Ultrasound of leg arteries or artery grafts | 16 | $3,759 | $235 |
| Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | 13 | $3,099 | $97 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 339 | $3,072 | $8 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $2,707 | $56 |
| Short return visit (20+ min) | 22 | $2,464 | $63 |
| Complete ultrasound study of arm and leg arteries | 19 | $2,437 | $128 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 42 | $1,875 | $8 |
| Annual depression screening, 5 to 15 minutes | 83 | $1,795 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 24 | $1,587 | $27 |
| Programming of dual lead pacemaker system | 21 | $1,578 | $54 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 18 | $1,479 | $82 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 19 | $1,314 | $29 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 16 | $1,122 | $66 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 46 | $1,040 | $6 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 44 | $1,012 | $18 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 20 | $590 | None |
| External ekg recording for more than 48 hours up to 21 days | 22 | $584 | $27 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 22 | $470 | $21 |
2014: 30 services
| Return visit (30+ min) | 588 | $108,920 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 265 | $61,957 | $222 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 117 | $32,634 | $272 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 64 | $31,814 | $497 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 64 | $25,180 | $132 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 158 | $21,225 | $134 |
| Long return visit (40+ min) | 135 | $20,265 | $124 |
| Short return visit (20+ min) | 139 | $13,910 | $58 |
| Ultrasound of both sides of head and neck blood flow | 69 | $13,569 | $194 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $9,856 | $92 |
| New patient visit (60+ min) | 40 | $7,352 | $184 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 371 | $6,461 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 78 | $5,017 | $64 |
| Ultrasound of leg arteries or artery grafts | 21 | $4,865 | $232 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 51 | $4,830 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,671 | $180 |
| Complete ultrasound study of arm and leg arteries | 28 | $3,969 | $142 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 118 | $3,379 | $15 |
| Annual depression screening, 5 to 15 minutes | 152 | $3,285 | $22 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 37 | $3,284 | $82 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 11 | $2,179 | $198 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 54 | $1,955 | $8 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 138 | $1,787 | $12 |
| New patient visit (45+ min) | 12 | $1,474 | $123 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 23 | $1,331 | $55 |
| Programming of dual lead pacemaker system | 14 | $1,049 | $55 |
| Blood test, clotting time | 63 | $878 | $5 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 17 | $633 | $32 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 34 | $440 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 12 | $82 | $7 |
2013: 37 services
| Return visit (30+ min) | 828 | $135,570 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 384 | $75,054 | $185 |
| Short return visit (20+ min) | 369 | $40,782 | $59 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 169 | $39,469 | $229 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 62 | $32,048 | $517 |
| Long return visit (40+ min) | 136 | $21,868 | $121 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $21,332 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 111 | $20,828 | $62 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 139 | $18,614 | $134 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 62 | $17,932 | $133 |
| Ultrasound of both sides of head and neck blood flow | 92 | $17,841 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $16,579 | $89 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 250 | $14,327 | $52 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 173 | $12,509 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 624 | $11,423 | $16 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 60 | $10,280 | None |
| New patient visit (60+ min) | 53 | $9,018 | $170 |
| Blood test, clotting time | 142 | $7,349 | $5 |
| New patient visit (45+ min) | 51 | $6,817 | $134 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 12 | $6,362 | $489 |
| Complete ultrasound study of arm and leg arteries | 41 | $6,266 | $146 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 64 | $6,008 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $5,848 | $112 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $5,345 | $445 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 70 | $4,792 | $68 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 20 | $4,327 | $216 |
| Ultrasound of leg arteries or artery grafts | 20 | $3,925 | $196 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 80 | $3,054 | $31 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 24 | $1,976 | $55 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 111 | $1,928 | $6 |
| New patient visit (30+ min) | 17 | $1,686 | $99 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 150 | $1,327 | $7 |
| Short return visit | 28 | $1,009 | $35 |
| Programming of dual lead pacemaker system | 16 | $898 | $53 |
| Hospital discharge day management, 30 minutes or less | 12 | $833 | $64 |
| Annual depression screening, 5 to 15 minutes | 24 | $534 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 13 | $86 | $6 |
Medicaid work
$1,421 in 2024
Medicaid paid $1,421 for 271 billed services this clinician did in 2024, up to 123 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 271 | $1,421 |
| 2024 | 271 | 1 | 123 | $1,421 |
| 2023 | 218 | 1 | 99 | $902 |
| 2022 | 168 | 1 | 74 | $655 |
| 2021 | 156 | 1 | 77 | $742 |
| 2020 | 123 | 1 | 61 | $476 |
| 2019 | 129 | 1 | 69 | $622 |
| 2018 | 147 | 1 | 66 | $614 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 218 | $902 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 168 | $655 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 156 | $742 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 123 | $476 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 129 | $622 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 147 | $614 |
Drugs they prescribed that Part D paid
$645,078
Pharmacies billed $645,078 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
2,844 generic and fewer than 11 brand-name prescriptions · $645,078 in drug cost · 15 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 156 | $224,172 | $1,437 |
| Xarelto | 78 | $127,806 | $1,639 |
| Ozempic | 67 | $75,699 | $1,130 |
| Entresto | 46 | $64,366 | $1,399 |
| Jardiance | 41 | $49,964 | $1,219 |
See all 54 drugs
| Eliquis | 156 | $224,172 | $1,437 |
| Xarelto | 78 | $127,806 | $1,639 |
| Ozempic | 67 | $75,699 | $1,130 |
| Entresto | 46 | $64,366 | $1,399 |
| Jardiance | 41 | $49,964 | $1,219 |
| Rosuvastatin | 366 | $5,659 | $15 |
| Valsartan | 96 | $3,683 | $38 |
| Metoprolol | 242 | $3,345 | $14 |
| Potassium Chloride | 106 | $3,042 | $29 |
| Verapamil Er | 57 | $2,595 | $46 |
| Verapamil Sr | 26 | $2,434 | $94 |
| Losartan | 224 | $2,416 | $11 |
| Diltiazem 24hr Er (Cd) | 48 | $2,078 | $43 |
| Colchicine | 11 | $2,012 | $183 |
| Atorvastatin | 171 | $1,995 | $12 |
| Amlodipine Besylate | 225 | $1,726 | $8 |
| Ezetimibe | 52 | $1,475 | $28 |
| Labetalol | 35 | $1,346 | $38 |
| Nitroglycerin | 24 | $961 | $40 |
| Bisoprolol-Hydrochlorothiazide | 19 | $950 | $50 |
| Diltiazem 24hr Er | 21 | $858 | $41 |
| Propranolol Hcl Er | 12 | $834 | $69 |
| Nitroglycerin Patch | 19 | $813 | $43 |
| Digoxin | 21 | $796 | $38 |
| Losartan-Hydrochlorothiazide | 55 | $709 | $13 |
| Levothyroxine | 47 | $681 | $14 |
| Metformin | 75 | $659 | $9 |
| Propranolol | 20 | $659 | $33 |
| Famotidine | 26 | $574 | $22 |
| Clopidogrel | 28 | $567 | $20 |
| Spironolactone-Hctz | 15 | $482 | $32 |
| Valsartan-Hydrochlorothiazide | 19 | $468 | $25 |
| Lisinopril | 40 | $443 | $11 |
| Pravastatin | 30 | $413 | $14 |
| Furosemide | 49 | $412 | $8 |
| Telmisartan | 16 | $410 | $26 |
| Allopurinol | 32 | $384 | $12 |
| Escitalopram | 14 | $331 | $24 |
| Zolpidem | 17 | $323 | $19 |
| Carvedilol | 63 | $318 | $5 |
| Clonidine | 38 | $312 | $8 |
| Chlorthalidone | 16 | $309 | $19 |
| Warfarin | 26 | $266 | $10 |
| Ramipril | 34 | $256 | $8 |
| Hydrochlorothiazide | 76 | $221 | $3 |
| Trazodone | 15 | $208 | $14 |
| Simvastatin | 16 | $204 | $13 |
| Gabapentin | 19 | $202 | $11 |
| Metoprolol | 24 | $195 | $8 |
| Klor-Con 10 | 14 | $184 | $13 |
| Metformin Hcl Er | 14 | $137 | $10 |
| Citalopram Hbr | 12 | $137 | $11 |
| Omeprazole | 19 | $110 | $6 |
| Alprazolam | 20 | $65 | $3 |
Year by year
| 2024 | 3,409 | 406 | None | None | $645,078 |
| 2023 | 3,547 | 403 | None | None | $765,234 |
| 2022 | 3,497 | 390 | None | None | $640,481 |
| 2021 | 3,520 | 375 | None | 15% | $560,641 |
| 2020 | 3,395 | 333 | None | 17% | $485,184 |
| 2019 | 3,320 | 340 | None | 17% | $427,716 |
| 2018 | 2,966 | 323 | None | 16% | $344,537 |
| 2017 | 3,069 | 314 | 1% (21) | None | $301,211 |
| 2016 | 3,212 | 321 | None | None | $293,898 |
| 2015 | 3,197 | 308 | None | None | $270,392 |
| 2014 | 3,475 | 312 | 1% (25) | None | $253,555 |
| 2013 | 3,772 | 343 | 0% (16) | None | $231,965 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 55 drugs
| Eliquis | 159 | $219,373 | $1,380 |
| Xarelto | 119 | $180,504 | $1,517 |
| Ozempic | 68 | $95,010 | $1,397 |
| Entresto | 53 | $79,571 | $1,501 |
| Jardiance | 33 | $39,595 | $1,200 |
| Farxiga | 21 | $27,069 | $1,289 |
| Mounjaro | 11 | $16,514 | $1,501 |
| Rosuvastatin | 372 | $9,170 | $25 |
| Diltiazem 24hr Er (Cd) | 50 | $4,614 | $92 |
| Metoprolol | 202 | $4,442 | $22 |
| Potassium Chloride | 131 | $3,450 | $26 |
| Colchicine | 13 | $3,427 | $264 |
| Verapamil Sr | 32 | $3,411 | $107 |
| Valsartan | 100 | $3,088 | $31 |
| Amlodipine Besylate | 273 | $2,786 | $10 |
| Losartan | 222 | $2,752 | $12 |
| Verapamil Er | 36 | $2,701 | $75 |
| Atorvastatin | 169 | $2,412 | $14 |
| Losartan-Hydrochlorothiazide | 65 | $1,532 | $24 |
| Labetalol | 33 | $1,460 | $44 |
| Ezetimibe | 31 | $1,260 | $41 |
| Chlorthalidone | 34 | $1,234 | $36 |
| Metformin | 76 | $909 | $12 |
| Propranolol Hcl Er | 13 | $766 | $59 |
| Famotidine | 25 | $727 | $29 |
| Diltiazem 24hr Er | 17 | $726 | $43 |
| Hydrochlorothiazide | 87 | $723 | $8 |
| Valsartan-Hydrochlorothiazide | 15 | $698 | $47 |
| Clopidogrel | 30 | $682 | $23 |
| Carvedilol | 57 | $681 | $12 |
| Warfarin | 36 | $668 | $19 |
| Spironolactone-Hctz | 13 | $668 | $51 |
| Levothyroxine | 44 | $659 | $15 |
| Propranolol | 23 | $616 | $27 |
| Clonidine | 46 | $606 | $13 |
| Pravastatin | 29 | $596 | $21 |
| Simvastatin | 38 | $580 | $15 |
| Digoxin | 18 | $479 | $27 |
| Allopurinol | 34 | $426 | $13 |
| Klor-Con 10 | 19 | $410 | $22 |
| Omeprazole | 17 | $367 | $22 |
| Gabapentin | 22 | $362 | $16 |
| Telmisartan | 17 | $346 | $20 |
| Zolpidem | 15 | $300 | $20 |
| Lisinopril | 40 | $298 | $7 |
| Furosemide | 57 | $296 | $5 |
| Atenolol | 18 | $291 | $16 |
| Ramipril | 23 | $264 | $11 |
| Metoprolol | 26 | $243 | $9 |
| Escitalopram | 17 | $221 | $13 |
| Citalopram Hbr | 21 | $208 | $10 |
| Trazodone | 14 | $190 | $14 |
| Nitroglycerin | 13 | $166 | $13 |
| Metformin Hcl Er | 12 | $107 | $9 |
| Alprazolam | 17 | $45 | $3 |
2022: 53 drugs
| Eliquis | 156 | $194,368 | $1,246 |
| Xarelto | 128 | $172,522 | $1,348 |
| Entresto | 31 | $56,477 | $1,822 |
| Jardiance | 33 | $38,582 | $1,169 |
| Ozempic | 34 | $35,246 | $1,037 |
| Farxiga | 23 | $25,235 | $1,097 |
| Rosuvastatin | 320 | $10,065 | $31 |
| Pradaxa | 11 | $5,819 | $529 |
| Diltiazem 24hr Er (Cd) | 70 | $5,434 | $78 |
| Verapamil Sr | 30 | $5,385 | $179 |
| Potassium Chloride | 155 | $5,109 | $33 |
| Metoprolol | 215 | $4,916 | $23 |
| Valsartan | 94 | $3,891 | $41 |
| Atorvastatin | 203 | $3,292 | $16 |
| Losartan | 186 | $2,503 | $13 |
| Labetalol | 43 | $2,358 | $55 |
| Amlodipine Besylate | 290 | $2,281 | $8 |
| Verapamil Er | 29 | $1,802 | $62 |
| Valsartan-Hydrochlorothiazide | 32 | $1,709 | $53 |
| Warfarin | 43 | $1,684 | $39 |
| Ezetimibe | 30 | $1,387 | $46 |
| Diltiazem 24hr Er | 22 | $1,356 | $62 |
| Losartan-Hydrochlorothiazide | 52 | $1,328 | $26 |
| Chlorthalidone | 35 | $1,109 | $32 |
| Levothyroxine | 50 | $1,002 | $20 |
| Lisinopril | 47 | $943 | $20 |
| Carvedilol | 52 | $878 | $17 |
| Metformin | 78 | $836 | $11 |
| Clopidogrel | 34 | $757 | $22 |
| Pravastatin | 26 | $655 | $25 |
| Digoxin | 16 | $601 | $38 |
| Allopurinol | 31 | $582 | $19 |
| Clonidine | 54 | $544 | $10 |
| Hydralazine | 11 | $490 | $45 |
| Furosemide | 55 | $469 | $9 |
| Atenolol | 30 | $435 | $15 |
| Propranolol | 16 | $413 | $26 |
| Telmisartan | 19 | $406 | $21 |
| Klor-Con 10 | 14 | $391 | $28 |
| Simvastatin | 30 | $384 | $13 |
| Hydrochlorothiazide | 65 | $351 | $5 |
| Tamsulosin | 20 | $350 | $18 |
| Famotidine | 17 | $324 | $19 |
| Zolpidem | 21 | $319 | $15 |
| Gabapentin | 16 | $221 | $14 |
| Metoprolol | 25 | $211 | $8 |
| Escitalopram | 17 | $209 | $12 |
| Omeprazole | 19 | $208 | $11 |
| Benazepril | 13 | $155 | $12 |
| Citalopram Hbr | 20 | $134 | $7 |
| Ramipril | 17 | $126 | $7 |
| Alprazolam | 20 | $35 | $2 |
| Amoxicillin | 11 | $10 | $1 |
2021: 58 drugs
| Xarelto | 150 | $187,054 | $1,247 |
| Eliquis | 137 | $167,662 | $1,224 |
| Entresto | 26 | $39,554 | $1,521 |
| Ozempic | 16 | $14,996 | $937 |
| Jardiance | 11 | $14,282 | $1,298 |
| Rosuvastatin | 309 | $10,793 | $35 |
| Diltiazem 24hr Er (Cd) | 71 | $7,264 | $102 |
| Potassium Chloride | 137 | $5,313 | $39 |
| Dexilant | 15 | $5,252 | $350 |
| Metoprolol | 176 | $4,272 | $24 |
| Verapamil Sr | 29 | $4,123 | $142 |
| Atorvastatin | 232 | $4,036 | $17 |
| Valsartan | 80 | $3,749 | $47 |
| Amlodipine Besylate | 295 | $2,802 | $9 |
| Losartan | 160 | $2,502 | $16 |
| Verapamil Er | 37 | $2,401 | $65 |
| Valsartan-Hydrochlorothiazide | 40 | $2,067 | $52 |
| Eplerenone | 11 | $1,816 | $165 |
| Diclofenac | 19 | $1,752 | $92 |
| Labetalol | 21 | $1,682 | $80 |
| Chlorthalidone | 45 | $1,467 | $33 |
| Diltiazem 24hr Er | 29 | $1,319 | $45 |
| Levothyroxine | 45 | $1,213 | $27 |
| Losartan-Hydrochlorothiazide | 44 | $1,208 | $27 |
| Carvedilol | 48 | $1,165 | $24 |
| Digoxin | 18 | $1,129 | $63 |
| Telmisartan | 16 | $1,026 | $64 |
| Warfarin | 54 | $1,025 | $19 |
| Metformin | 96 | $1,014 | $11 |
| Clonidine | 64 | $950 | $15 |
| Ezetimibe | 18 | $867 | $48 |
| Clopidogrel | 30 | $805 | $27 |
| Lisinopril | 56 | $801 | $14 |
| Propranolol | 30 | $699 | $23 |
| Allopurinol | 29 | $673 | $23 |
| Tamsulosin | 24 | $624 | $26 |
| Spironolactone-Hctz | 14 | $570 | $41 |
| Hydralazine | 12 | $556 | $46 |
| Furosemide | 62 | $541 | $9 |
| Simvastatin | 43 | $531 | $12 |
| Famotidine | 18 | $492 | $27 |
| Hydrochlorothiazide | 62 | $448 | $7 |
| Atenolol | 31 | $439 | $14 |
| Pantoprazole | 21 | $424 | $20 |
| Klor-Con 10 | 13 | $418 | $32 |
| Zolpidem | 19 | $369 | $19 |
| Pregabalin | 11 | $361 | $33 |
| Liothyronine | 13 | $346 | $27 |
| Ramipril | 22 | $334 | $15 |
| Escitalopram | 12 | $322 | $27 |
| Trazodone | 21 | $303 | $14 |
| Pravastatin | 14 | $271 | $19 |
| Benazepril | 22 | $265 | $12 |
| Lovastatin | 12 | $253 | $21 |
| Metoprolol | 33 | $205 | $6 |
| Spironolactone | 19 | $200 | $11 |
| Citalopram Hbr | 14 | $177 | $13 |
| Alprazolam | 18 | $14 | $1 |
2020: 60 drugs
| Eliquis | 145 | $147,923 | $1,020 |
| Xarelto | 129 | $140,443 | $1,089 |
| Entresto | 32 | $36,234 | $1,132 |
| Diltiazem 24hr Er (Cd) | 73 | $13,556 | $186 |
| Rosuvastatin | 244 | $13,466 | $55 |
| Dexilant | 23 | $7,288 | $317 |
| Potassium Chloride | 144 | $6,244 | $43 |
| Atorvastatin | 244 | $5,303 | $22 |
| Metoprolol | 130 | $4,703 | $36 |
| Januvia | 11 | $4,457 | $405 |
| Verapamil Sr | 31 | $3,332 | $107 |
| Losartan | 185 | $3,155 | $17 |
| Amlodipine Besylate | 306 | $3,045 | $10 |
| Losartan-Hydrochlorothiazide | 42 | $2,777 | $66 |
| Valsartan | 37 | $2,407 | $65 |
| Diclofenac | 25 | $2,293 | $92 |
| Eplerenone | 15 | $2,293 | $153 |
| Chlorthalidone | 42 | $2,057 | $49 |
| Verapamil Er | 27 | $1,930 | $71 |
| Valsartan-Hydrochlorothiazide | 40 | $1,803 | $45 |
| Telmisartan | 16 | $1,425 | $89 |
| Warfarin | 63 | $1,387 | $22 |
| Levothyroxine | 51 | $1,338 | $26 |
| Synthroid | 17 | $1,185 | $70 |
| Digoxin | 21 | $1,180 | $56 |
| Diltiazem 24hr Er | 20 | $1,107 | $55 |
| Labetalol | 15 | $1,079 | $72 |
| Clopidogrel | 34 | $1,008 | $30 |
| Pravastatin | 29 | $974 | $34 |
| Ezetimibe | 14 | $878 | $63 |
| Spironolactone-Hctz | 18 | $827 | $46 |
| Famotidine | 23 | $826 | $36 |
| Allopurinol | 26 | $750 | $29 |
| Simvastatin | 58 | $739 | $13 |
| Lisinopril | 39 | $736 | $19 |
| Furosemide | 67 | $721 | $11 |
| Carvedilol | 41 | $704 | $17 |
| Ramipril | 39 | $675 | $17 |
| Metformin | 66 | $622 | $9 |
| Pregabalin | 13 | $607 | $47 |
| Tamsulosin | 22 | $550 | $25 |
| Hydrochlorothiazide | 52 | $524 | $10 |
| Atenolol | 38 | $491 | $13 |
| Escitalopram | 15 | $475 | $32 |
| Clonidine | 39 | $451 | $12 |
| Trazodone | 28 | $399 | $14 |
| Esomeprazole Magnesium | 12 | $380 | $32 |
| Nitroglycerin | 16 | $377 | $24 |
| Benazepril | 20 | $363 | $18 |
| Pantoprazole | 20 | $336 | $17 |
| Sertraline | 18 | $284 | $16 |
| Zolpidem | 23 | $271 | $12 |
| Quetiapine | 15 | $222 | $15 |
| Triamterene-Hydrochlorothiazid | 11 | $199 | $18 |
| Gabapentin | 12 | $197 | $16 |
| Metoprolol | 28 | $191 | $7 |
| Spironolactone | 25 | $174 | $7 |
| Clonazepam | 15 | $160 | $11 |
| Alprazolam | 14 | $109 | $8 |
| Citalopram Hbr | 15 | $91 | $6 |
2019: 58 drugs
| Xarelto | 126 | $137,330 | $1,090 |
| Eliquis | 121 | $111,715 | $923 |
| Entresto | 18 | $19,141 | $1,063 |
| Rosuvastatin | 202 | $10,903 | $54 |
| Diltiazem 24hr Er (Cd) | 56 | $9,470 | $169 |
| Repatha Sureclick | 11 | $8,487 | $772 |
| Pentasa | 12 | $6,600 | $550 |
| Atorvastatin | 240 | $5,079 | $21 |
| Metoprolol | 124 | $4,950 | $40 |
| Potassium Chloride | 136 | $4,905 | $36 |
| Verapamil Sr | 42 | $4,780 | $114 |
| Dexilant | 12 | $3,356 | $280 |
| Verapamil | 13 | $3,293 | $253 |
| Chlorthalidone | 63 | $3,017 | $48 |
| Amlodipine Besylate | 274 | $2,967 | $11 |
| Losartan | 200 | $2,922 | $15 |
| Eplerenone | 13 | $2,244 | $173 |
| Warfarin | 83 | $2,197 | $26 |
| Valsartan-Hydrochlorothiazide | 37 | $1,779 | $48 |
| Digoxin | 32 | $1,723 | $54 |
| Diltiazem 24hr Er | 27 | $1,600 | $59 |
| Ezetimibe | 18 | $1,335 | $74 |
| Valsartan | 30 | $1,321 | $44 |
| Ramipril | 57 | $1,096 | $19 |
| Spironolactone-Hctz | 16 | $968 | $60 |
| Verapamil Er | 25 | $958 | $38 |
| Levothyroxine | 41 | $939 | $23 |
| Bupropion Xl | 13 | $914 | $70 |
| Carvedilol | 53 | $843 | $16 |
| Clopidogrel | 43 | $837 | $19 |
| Lisinopril | 56 | $785 | $14 |
| Losartan-Hydrochlorothiazide | 46 | $747 | $16 |
| Pravastatin | 35 | $742 | $21 |
| Simvastatin | 67 | $716 | $11 |
| Furosemide | 55 | $705 | $13 |
| Metformin | 70 | $659 | $9 |
| Nitroglycerin Patch | 11 | $635 | $58 |
| Allopurinol | 23 | $519 | $23 |
| Zolpidem | 26 | $489 | $19 |
| Atenolol | 38 | $488 | $13 |
| Hydrochlorothiazide | 47 | $437 | $9 |
| Liothyronine | 15 | $372 | $25 |
| Spironolactone | 28 | $364 | $13 |
| Metoprolol | 45 | $338 | $8 |
| Diclofenac | 14 | $318 | $23 |
| Escitalopram | 12 | $317 | $26 |
| Nitroglycerin | 11 | $299 | $27 |
| Pantoprazole | 14 | $289 | $21 |
| Tamsulosin | 16 | $286 | $18 |
| Benazepril | 22 | $282 | $13 |
| Esomeprazole Magnesium | 12 | $276 | $23 |
| Citalopram Hbr | 16 | $232 | $15 |
| Quetiapine | 12 | $182 | $15 |
| Sertraline | 16 | $162 | $10 |
| Triamterene-Hydrochlorothiazid | 11 | $152 | $14 |
| Ropinirole | 11 | $127 | $12 |
| Lovastatin | 13 | $118 | $9 |
| Clonazepam | 14 | $96 | $7 |
2018: 51 drugs
| Xarelto | 123 | $117,261 | $953 |
| Eliquis | 84 | $65,141 | $775 |
| Repatha Sureclick | 13 | $15,250 | $1,173 |
| Niacin Er | 11 | $7,561 | $687 |
| Advair Diskus | 12 | $7,470 | $622 |
| Rosuvastatin | 143 | $7,447 | $52 |
| Diltiazem 24hr Er (Cd) | 43 | $5,955 | $138 |
| Atorvastatin | 230 | $5,454 | $24 |
| Metoprolol | 115 | $5,066 | $44 |
| Eplerenone | 31 | $4,576 | $148 |
| Potassium Chloride | 117 | $3,701 | $32 |
| Verapamil Sr | 24 | $2,726 | $114 |
| Amlodipine Besylate | 233 | $2,529 | $11 |
| Warfarin | 86 | $2,391 | $28 |
| Verapamil Er | 40 | $2,209 | $55 |
| Diltiazem 24hr Er | 31 | $2,193 | $71 |
| Chlorthalidone | 46 | $2,002 | $44 |
| Ezetimibe | 20 | $1,936 | $97 |
| Losartan | 139 | $1,829 | $13 |
| Valsartan-Hydrochlorothiazide | 44 | $1,535 | $35 |
| Dilt-Xr | 20 | $1,414 | $71 |
| Ramipril | 72 | $1,398 | $19 |
| Spironolactone-Hctz | 23 | $1,154 | $50 |
| Digoxin | 25 | $1,102 | $44 |
| Pravastatin | 43 | $1,092 | $25 |
| Valsartan | 37 | $1,040 | $28 |
| Simvastatin | 97 | $959 | $10 |
| Digox | 12 | $931 | $78 |
| Cartia Xt | 13 | $905 | $70 |
| Levothyroxine | 36 | $881 | $24 |
| Metformin | 53 | $766 | $14 |
| Lisinopril | 65 | $763 | $12 |
| Omeprazole | 16 | $712 | $44 |
| Clopidogrel | 35 | $702 | $20 |
| Allopurinol | 25 | $541 | $22 |
| Tamsulosin | 21 | $520 | $25 |
| Carvedilol | 45 | $457 | $10 |
| Atenolol | 46 | $454 | $10 |
| Spironolactone | 38 | $446 | $12 |
| Losartan-Hydrochlorothiazide | 36 | $429 | $12 |
| Furosemide | 34 | $416 | $12 |
| Hydrochlorothiazide | 52 | $375 | $7 |
| Nitroglycerin | 11 | $310 | $28 |
| Citalopram Hbr | 18 | $265 | $15 |
| Metoprolol | 37 | $239 | $6 |
| Sertraline | 14 | $225 | $16 |
| Gabapentin | 14 | $199 | $14 |
| Triamterene-Hydrochlorothiazid | 11 | $187 | $17 |
| Klor-Con M20 | 11 | $162 | $15 |
| Lorazepam | 11 | $160 | $15 |
| Benazepril | 13 | $141 | $11 |
2017: 54 drugs
| Xarelto | 134 | $106,217 | $793 |
| Eliquis | 35 | $27,604 | $789 |
| Pradaxa | 18 | $13,357 | $742 |
| Repatha Sureclick | 11 | $13,052 | $1,187 |
| Entresto | 16 | $11,592 | $725 |
| Zetia | 13 | $8,175 | $629 |
| Rosuvastatin | 95 | $7,472 | $79 |
| Niacin Er | 14 | $7,268 | $519 |
| Atorvastatin | 260 | $6,184 | $24 |
| Potassium Chloride | 130 | $6,178 | $48 |
| Metoprolol | 100 | $5,227 | $52 |
| Diltiazem 24hr Er | 73 | $4,019 | $55 |
| Verapamil | 14 | $3,941 | $282 |
| Warfarin | 116 | $3,034 | $26 |
| Verapamil Er | 54 | $2,624 | $49 |
| Amlodipine Besylate | 250 | $2,246 | $9 |
| Verapamil Sr | 20 | $2,181 | $109 |
| Spironolactone-Hctz | 47 | $2,135 | $45 |
| Eplerenone | 12 | $1,894 | $158 |
| Dilt-Xr | 25 | $1,711 | $68 |
| Pravastatin | 52 | $1,511 | $29 |
| Ramipril | 93 | $1,505 | $16 |
| Losartan | 110 | $1,416 | $13 |
| Bumetanide | 13 | $1,410 | $108 |
| Digoxin | 21 | $1,375 | $65 |
| Simvastatin | 109 | $1,205 | $11 |
| Livalo | 12 | $1,196 | $100 |
| Valsartan | 30 | $1,190 | $40 |
| Omeprazole | 39 | $1,160 | $30 |
| Lisinopril | 80 | $866 | $11 |
| Clopidogrel | 52 | $835 | $16 |
| Cartia Xt | 18 | $766 | $43 |
| Hydrochlorothiazide | 68 | $699 | $10 |
| Levothyroxine | 30 | $671 | $22 |
| Tamsulosin | 20 | $657 | $33 |
| Allopurinol | 33 | $648 | $20 |
| Furosemide | 61 | $563 | $9 |
| Spironolactone | 55 | $542 | $10 |
| Metformin | 40 | $481 | $12 |
| Carvedilol | 53 | $419 | $8 |
| Atenolol | 55 | $367 | $7 |
| Losartan-Hydrochlorothiazide | 26 | $295 | $11 |
| Gabapentin | 26 | $287 | $11 |
| Citalopram Hbr | 30 | $284 | $9 |
| Lorazepam | 19 | $259 | $14 |
| Metoprolol | 34 | $198 | $6 |
| Benazepril | 18 | $196 | $11 |
| Diltiazem Er | 11 | $176 | $16 |
| Trazodone | 11 | $123 | $11 |
| Lovastatin | 15 | $120 | $8 |
| Sertraline | 19 | $99 | $5 |
| Clonazepam | 11 | $83 | $8 |
| Quinapril | 11 | $75 | $7 |
| Tramadol | 13 | $32 | $2 |
2016: 54 drugs
| Xarelto | 125 | $91,138 | $729 |
| Crestor | 69 | $32,882 | $477 |
| Pradaxa | 32 | $17,768 | $555 |
| Eliquis | 20 | $9,795 | $490 |
| Atorvastatin | 314 | $8,066 | $26 |
| Potassium Chloride | 111 | $7,421 | $67 |
| Niacin Er | 28 | $7,286 | $260 |
| Metoprolol | 118 | $4,966 | $42 |
| Diltiazem 24hr Er | 66 | $4,593 | $70 |
| Zetia | 13 | $4,120 | $317 |
| Rosuvastatin | 33 | $3,483 | $106 |
| Warfarin | 176 | $3,454 | $20 |
| Ramipril | 94 | $2,633 | $28 |
| Dilt-Xr | 35 | $2,524 | $72 |
| Amlodipine Besylate | 246 | $2,516 | $10 |
| Spironolactone-Hctz | 41 | $1,957 | $48 |
| Verapamil Er | 40 | $1,666 | $42 |
| Pravastatin | 54 | $1,544 | $29 |
| Digoxin | 34 | $1,526 | $45 |
| Losartan | 117 | $1,514 | $13 |
| Lisinopril | 97 | $1,205 | $12 |
| Simvastatin | 130 | $1,107 | $9 |
| Spironolactone | 72 | $915 | $13 |
| Valsartan | 32 | $873 | $27 |
| Omeprazole | 29 | $834 | $29 |
| Carvedilol | 47 | $691 | $15 |
| Flunisolide | 13 | $674 | $52 |
| Ranitidine | 11 | $672 | $61 |
| Benazepril-Hydrochlorothiazide | 14 | $643 | $46 |
| Hydrochlorothiazide | 62 | $629 | $10 |
| Clopidogrel | 40 | $601 | $15 |
| Atenolol | 73 | $597 | $8 |
| Nitrostat | 19 | $590 | $31 |
| Allopurinol | 28 | $580 | $21 |
| Levothyroxine | 22 | $531 | $24 |
| Furosemide | 51 | $516 | $10 |
| Metformin | 41 | $483 | $12 |
| Phenytoin Sodium Extended | 11 | $452 | $41 |
| Citalopram Hbr | 22 | $357 | $16 |
| Quinapril | 21 | $351 | $17 |
| Losartan-Hydrochlorothiazide | 27 | $351 | $13 |
| Metoprolol | 42 | $300 | $7 |
| Lovastatin | 18 | $288 | $16 |
| Pantoprazole | 19 | $252 | $13 |
| Ipratropium | 14 | $250 | $18 |
| Trazodone | 20 | $215 | $11 |
| Fosinopril | 12 | $208 | $17 |
| Diltiazem Er | 11 | $189 | $17 |
| Valsartan-Hydrochlorothiazide | 11 | $176 | $16 |
| Lorazepam | 13 | $174 | $13 |
| Benazepril | 14 | $125 | $9 |
| Clonazepam | 17 | $125 | $7 |
| Bupropion Hcl Sr | 11 | $122 | $11 |
| Sertraline | 24 | $90 | $4 |
2015: 56 drugs
| Xarelto | 141 | $83,610 | $593 |
| Crestor | 86 | $32,302 | $376 |
| Pradaxa | 32 | $13,171 | $412 |
| Niacin Er | 20 | $10,032 | $502 |
| Eliquis | 16 | $8,135 | $508 |
| Atorvastatin | 228 | $6,530 | $29 |
| Potassium Chloride | 132 | $4,747 | $36 |
| Warfarin | 219 | $4,227 | $19 |
| Metoprolol | 91 | $4,115 | $45 |
| Benicar | 16 | $3,655 | $228 |
| Ramipril | 84 | $2,744 | $33 |
| Digoxin | 37 | $2,736 | $74 |
| Pravastatin | 65 | $2,550 | $39 |
| Diltiazem Er | 57 | $2,452 | $43 |
| Spironolactone-Hctz | 44 | $2,390 | $54 |
| Amlodipine Besylate | 215 | $1,880 | $9 |
| Valsartan | 27 | $1,810 | $67 |
| Diltiazem 24hr Er | 26 | $1,584 | $61 |
| Carvedilol | 63 | $1,150 | $18 |
| Verapamil Er | 22 | $1,145 | $52 |
| Losartan | 94 | $1,094 | $12 |
| Bumetanide | 12 | $1,076 | $90 |
| Dilt-Xr | 20 | $1,056 | $53 |
| Omeprazole | 33 | $1,046 | $32 |
| Allopurinol | 30 | $932 | $31 |
| Lisinopril | 105 | $927 | $9 |
| Levothyroxine | 40 | $846 | $21 |
| Simvastatin | 123 | $837 | $7 |
| Hydrochlorothiazide | 70 | $765 | $11 |
| Raloxifene | 11 | $738 | $67 |
| Ranitidine | 11 | $722 | $66 |
| Clopidogrel | 31 | $704 | $23 |
| Nitroglycerin Patch | 15 | $666 | $44 |
| Quinapril | 22 | $598 | $27 |
| Spironolactone | 63 | $539 | $9 |
| Amlodipine Besylate-Benazepril | 12 | $508 | $42 |
| Ipratropium | 17 | $491 | $29 |
| Lovastatin | 34 | $489 | $14 |
| Atenolol | 74 | $467 | $6 |
| Citalopram Hbr | 29 | $422 | $15 |
| Furosemide | 59 | $413 | $7 |
| Nitrostat | 15 | $385 | $26 |
| Losartan-Hydrochlorothiazide | 33 | $360 | $11 |
| Metoprolol | 55 | $354 | $6 |
| Metformin | 34 | $336 | $10 |
| Latanoprost | 11 | $314 | $29 |
| Phenytoin Sodium Extended | 12 | $309 | $26 |
| Amiodarone | 13 | $299 | $23 |
| Fosinopril | 14 | $284 | $20 |
| Pantoprazole | 14 | $230 | $16 |
| Trazodone | 28 | $222 | $8 |
| Benazepril | 16 | $138 | $9 |
| Zolpidem | 11 | $136 | $12 |
| Bupropion Hcl Sr | 12 | $99 | $8 |
| Clonazepam | 12 | $74 | $6 |
| Sertraline | 22 | $68 | $3 |
2014: 55 drugs
| Xarelto | 113 | $51,858 | $459 |
| Crestor | 84 | $29,670 | $353 |
| Niacin Er | 35 | $18,649 | $533 |
| Pradaxa | 29 | $12,173 | $420 |
| Diovan | 23 | $8,215 | $357 |
| Atorvastatin | 218 | $6,220 | $29 |
| Warfarin | 295 | $4,669 | $16 |
| Metoprolol | 76 | $4,279 | $56 |
| Benicar | 23 | $3,914 | $170 |
| Ramipril | 113 | $3,844 | $34 |
| Potassium Chloride | 128 | $3,652 | $29 |
| Pravastatin | 85 | $2,980 | $35 |
| Digoxin | 46 | $2,959 | $64 |
| Diltiazem Er | 54 | $2,615 | $48 |
| Amlodipine Besylate | 227 | $2,261 | $10 |
| Digox | 47 | $2,169 | $46 |
| Verapamil Er | 35 | $1,799 | $51 |
| Amlodipine Besylate-Benazepril | 29 | $1,659 | $57 |
| Omeprazole | 45 | $1,523 | $34 |
| Spironolactone-Hctz | 38 | $1,481 | $39 |
| Carvedilol | 74 | $1,360 | $18 |
| Losartan | 108 | $1,357 | $13 |
| Diltiazem 24hr Er | 33 | $1,339 | $41 |
| Simvastatin | 162 | $1,333 | $8 |
| Cartia Xt | 23 | $1,213 | $53 |
| Ranitidine | 12 | $811 | $68 |
| Lisinopril | 85 | $809 | $10 |
| Clopidogrel | 25 | $783 | $31 |
| Valsartan-Hydrochlorothiazide | 16 | $759 | $47 |
| Quinapril | 21 | $708 | $34 |
| Levothyroxine | 42 | $660 | $16 |
| Klor-Con 10 | 16 | $618 | $39 |
| Losartan-Hydrochlorothiazide | 33 | $602 | $18 |
| Hydrochlorothiazide | 65 | $587 | $9 |
| Atenolol | 83 | $583 | $7 |
| Lovastatin | 40 | $580 | $15 |
| Tamsulosin | 20 | $469 | $23 |
| Spironolactone | 50 | $456 | $9 |
| Metformin | 36 | $450 | $13 |
| Furosemide | 79 | $450 | $6 |
| Fosinopril | 15 | $348 | $23 |
| Amiodarone | 25 | $334 | $13 |
| Zolpidem | 28 | $330 | $12 |
| Allopurinol | 23 | $327 | $14 |
| Metoprolol | 45 | $303 | $7 |
| Citalopram Hbr | 21 | $267 | $13 |
| Benazepril | 19 | $260 | $14 |
| Bisoprolol-Hydrochlorothiazide | 14 | $244 | $17 |
| Bupropion Hcl Sr | 13 | $226 | $17 |
| Doxazosin Mesylate | 12 | $225 | $19 |
| Phenytoin Sodium Extended | 12 | $204 | $17 |
| Trazodone | 29 | $191 | $7 |
| Gemfibrozil | 12 | $155 | $13 |
| Tramadol | 13 | $109 | $8 |
| Sertraline | 12 | $59 | $5 |
2013: 61 drugs
| Niaspan | 64 | $28,998 | $453 |
| Crestor | 83 | $25,011 | $301 |
| Xarelto | 69 | $20,676 | $300 |
| Atorvastatin | 267 | $9,903 | $37 |
| Welchol | 14 | $9,613 | $687 |
| Pradaxa | 28 | $9,534 | $341 |
| Diovan | 29 | $8,011 | $276 |
| Simcor | 13 | $7,344 | $565 |
| Warfarin | 365 | $4,801 | $13 |
| Benicar | 32 | $4,348 | $136 |
| Niacin Er | 12 | $4,125 | $344 |
| Metoprolol | 77 | $3,961 | $51 |
| Potassium Chloride | 106 | $3,686 | $35 |
| Ramipril | 140 | $3,309 | $24 |
| Verapamil Er | 79 | $3,119 | $39 |
| Clopidogrel | 48 | $3,093 | $64 |
| Amlodipine Besylate | 284 | $2,982 | $10 |
| Losartan | 104 | $2,705 | $26 |
| Amlodipine Besylate-Benazepril | 34 | $2,597 | $76 |
| Pravastatin | 116 | $2,433 | $21 |
| Diltiazem Er | 44 | $2,418 | $55 |
| Celebrex | 12 | $2,033 | $169 |
| Omeprazole | 42 | $1,884 | $45 |
| Carvedilol | 67 | $1,512 | $23 |
| Valsartan-Hydrochlorothiazide | 23 | $1,435 | $62 |
| Simvastatin | 127 | $1,319 | $10 |
| Cartia Xt | 16 | $1,247 | $78 |
| Lisinopril | 128 | $1,230 | $10 |
| Klor-Con 10 | 33 | $1,089 | $33 |
| Spironolactone-Hctz | 53 | $1,047 | $20 |
| Quinapril | 23 | $1,021 | $44 |
| Digox | 77 | $952 | $12 |
| Metformin | 45 | $787 | $17 |
| Losartan-Hydrochlorothiazide | 34 | $737 | $22 |
| Diltiazem 24hr Er | 18 | $733 | $41 |
| Hydrochlorothiazide | 63 | $650 | $10 |
| Tamsulosin | 19 | $645 | $34 |
| Venlafaxine Hcl Er | 11 | $607 | $55 |
| Diltiazem 24hr Cd | 12 | $551 | $46 |
| Furosemide | 84 | $542 | $6 |
| Lovastatin | 37 | $538 | $15 |
| Atenolol | 75 | $498 | $7 |
| Amiodarone | 30 | $417 | $14 |
| Benazepril | 19 | $403 | $21 |
| Metoprolol | 45 | $399 | $9 |
| Levothyroxine | 39 | $367 | $9 |
| Spironolactone | 38 | $347 | $9 |
| Citalopram Hbr | 37 | $337 | $9 |
| Zolpidem | 44 | $321 | $7 |
| Bisoprolol-Hydrochlorothiazide | 21 | $318 | $15 |
| Digoxin | 25 | $314 | $13 |
| Nitrostat | 13 | $312 | $24 |
| Methyldopa | 24 | $308 | $13 |
| Klor-Con M10 | 13 | $258 | $20 |
| Allopurinol | 20 | $223 | $11 |
| Fosinopril | 11 | $204 | $19 |
| Clonazepam | 12 | $129 | $11 |
| Trazodone | 15 | $110 | $7 |
| Doxazosin Mesylate | 12 | $74 | $6 |
| Sertraline | 11 | $64 | $6 |
| Alprazolam | 14 | $60 | $4 |
Money from drug and device companies
$35 in 2025
| 2025 | 1 | 1 | None | $35 |
| 2024 | 1 | 1 | None | $43 |
| 2023 | 1 | 1 | None | $36 |
| 2021 | 1 | 1 | None | $22 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| PolyNovo North America | Novosorb Btm | $35 | 1 payment
|
See the published payment
| PolyNovo North America | Meals · 2025-07-17 | Novosorb Btm | $35 |
See earlier years (2024, 2023, 2021)
2024: $43
| Biotronik | None | $43 | 1 payment
|
2023: $36
| Biotronik | Edora 8 Dr-T | $36 | 1 payment
|
2021: $22
| Biotronik | Rivacor | $22 | 1 payment
|
Checkups this office reported
17 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 89.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 41%That's less than half. | 919 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 74%That's more than half. | 356 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 0%That's few of the people this applied to. Better on this measure. | 60 |
| Breast cancer screeningEligible women who got a mammogram | 56%That's more than half. | 203 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 25%That's less than half. | 182 |
| Checked for fall riskOlder patients screened for fall risk | 10%That's few of the people this applied to. | 640 |
| Colon cancer screeningEligible adults who got a colon cancer test | 47%That's less than half. | 707 |
| Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <= 40%)As Medicare defines this measure | 73% | 22 |
See the other 9 measures
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 9%That's few of the people this applied to. | 1,067 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 4%That's few of the people this applied to. | 136 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 65%That's more than half. Worse on this measure. | 136 |
| HIV screeningEligible patients who were screened for HIV | 12%That's few of the people this applied to. | 600 |
| Medications listed in the chartVisits where the current medication list was documented | 96%That's most of the people this applied to. | 3,095 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 539 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 869 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 85%That's most of the people this applied to. | 698 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 53%That's more than half. | 1,186 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Improved the patient portal
- Lets patients read their visit notes
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
Professional record
- NPI
- 1811912975
- Licence
- CA G45862California G45862: Current · expires 2027-03-31
- Trained
- Yale University School of Medicine, 1980
- Group
- El Camino Health Medical Network LLC · Physician Services at El Camino Hospital
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 2490 Hospital Dr Ste 309, Mountain View, CA, 94040
- NPI first listed
- 2006-07-12
- NPI last updated
- 2025-03-03
- NPI record certified
- 2025-03-03
This is when the NPI record was last certified, not a medical board exam.